---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-001397"
form_type: "8-K"
ticker: "SNWV"
cik: "0001417663"
company_name: "SANUWAVE Health, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:52:15.033852+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sanuwave announces preliminary Q4 2024 revenue of $10.1-10.3M, record high, up 44-47% YoY

## Summary
- Q4 2024 revenue expected $10.1-10.3M, highest quarterly revenue in company history; increase of 44-47% YoY.
- UltraMist revenue up >54% vs Q4 2023, representing ~98% of total Q4 revenue; applicator sales all-time record ~58% of total.
- Full year 2024 preliminary revenue $32.4-32.6M, up 59-60% vs 2023.
- CEO Morgan Frank cites third consecutive record quarter and 'breakout year' targeting rapid profitable growth.
- Company expects to release complete Q4 and FY2024 results in March 2025.

## SEC filing metadata
- accession: 0001628280-25-001397
- form_type: 8-K
- ticker: SNWV
- cik: 0001417663
- company_name: SANUWAVE Health, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417663/000162828025001397/0001628280-25-001397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417663/000162828025001397/snwv-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-001397
- JSON: https://secwatch.observer/filing/0001628280-25-001397.json
- Plain text: https://secwatch.observer/filing/0001628280-25-001397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.